Heliad Equity Partners GmbH & Co. KGaA / Miscellaneous
Corporate news transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
++ Heliad portfolio investment Vanguard concludes major deal worth EUR 180
million in the UK
++ Takeover of sterile supply services and instrument management at BMI
Healthcare, the largest private hospital chain in Great Britain
The Berlin-based high-tech medical services provider Vanguard, a portfolio
investment of Heliad Equity Partners, has recently announced it will
takeover the provision of sterile supply services and instrument management
for the UK hospital chain BMI Healthcare. The BMI Healthcare Group
comprises 49 private maximum care hospitals in the United Kingdom with a
total of more than 2,400 beds. Around 250,000 in-patients and 750,000
out-patients are cared for each year. As a subsidiary of the General Health
Care Group (GHG), BMI is part of one of the leading private hospital chains
in Great Britain.
According to information provided by Vanguard, the total order volume
amounts to around EUR 180 million, spread over an initial term of
12 years. Vanguard will install several new systems for GHG, which will be
used to guarantee the provision of healthcare services to the total of 117
operation theatres via an advanced logistics system, which is also yet to
be installed. Two existing systems in Glasgow and Manchester will also be
supported from February 2007. This will be followed immediately afterwards
by the construction of four further high-tech care centres with scalable
care capacities in North Kent, North West London, South West London and
Birmingham. In future these centres could also provide care for further
clinics in the area.
For Heliad Managing Director Andreas Lange, the deal with BMI/GHG
represents a significant milestone in Vanguard’s development: 'Having
already made an extremely successful market entry in a number of European
countries, in securing this major deal, the German market leader Vanguard
has provided further evidence that its expansion abroad is on an extremely
solid footing. At the same time, the long-running contracts with the
clinics are generating high income stability and predictability, making it
possible to plan Vanguard’s future success with a high degree of
certainty.'
Contact:
Heliad Equity Partners GmbH & Co. KGaA
Christiane Kriesche
Leiterin Marketing & Kommunikation
Grüneburgweg 18
60322 Frankfurt
Tel.: +49(0)69 719 15 965 17
Fax: +49(0)69 719 15 965 17
E-Mail: christiane.kriesche@sigma-capital.de
DGAP 17.01.2007
Language: English
Issuer: Heliad Equity Partners GmbH & Co. KGaA
Grüneburgweg 18
60322 Frankfurt am Main Deutschland
Phone: +49 (0)69 719 15 965 0
Fax: +49(0)69 719 15 965 11
E-mail: christiane.kriesche@sigma-capital.de
WWW: www.heliad.de
ISIN: DE0006047293
WKN: 604729
Indices:
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin-Bremen, München, Stuttgart
End of News DGAP News-Service